COR

Earnings Release Announcement: Cencora, Inc. will release its Q2 Fiscal 2025 results on May 7, 2025, before NYSE trading opens and will host a conference call at 8:30 a.m. ET to discuss the results.

Company Overview: Cencora is a global pharmaceutical solutions organization focused on enhancing health outcomes, ranked #10 on the Fortune 500 with over $290 billion in annual revenue.

AdvisorShares Focused Equity ETF Performance: The AdvisorShares Focused Equity ETF, managed by Eddy Elfenbein, is outperforming the market in 2025 with a five-star Morningstar rating, primarily due to its conservative stock holdings and low turnover strategy.

Investor Advice During Market Volatility: Elfenbein advises investors to maintain a long-term focus and not panic during market fluctuations, emphasizing the importance of holding quality stocks that can endure volatility.

CENCORA INC Analysis: CENCORA INC (COR) has received a 66% rating from Validea's P/B Growth Investor model, indicating potential for future growth based on its fundamentals and valuation in the Major Drugs industry.

Partha Mohanram's Contribution: Partha Mohanram, an academic and expert in value investing, developed a growth model that challenges traditional views, focusing on criteria to identify sustainable growth stocks, which he detailed in his influential research paper.

Company Overview: Cardinal Health, Inc. is a major global healthcare solutions provider with a market capitalization of $31.9 billion, operating in over 30 countries and employing more than 48,000 professionals, focusing on pharmaceutical distribution and healthcare logistics.

Stock Performance: CAH stock has seen significant growth, gaining 12.5% over the past three months and reaching an all-time high of $133.11, with analysts rating it as a "Strong Buy" and a mean price target of $142.19, indicating continued bullish momentum amidst market volatility.

Analyst Ratings Overview: Cencora has received mixed analyst ratings over the past three months, with recent evaluations showing a shift towards more bullish sentiments and an average 12-month price target of $276.5, reflecting a 5.64% increase from previous estimates.

Financial Performance Highlights: Cencora demonstrates strong financial metrics, including a revenue growth rate of 12.78%, a net margin of 0.6%, and an impressive return on equity of 112.0%, although it has a higher debt-to-equity ratio compared to industry standards.

Earnings Outlook: Cencora, a medical supplies distributor, has raised its earnings outlook for 2025.

Stock Performance: The company's stock is approaching a buy point after forming a new base.

Cencora's Market Performance: Cencora, Inc. has a market cap of $50.5 billion and operates in pharmaceutical distribution, showing resilience with a 12.4% share increase over the past three months despite a slight decline from its 52-week high. The company reported strong Q1 2025 earnings, surpassing forecasts, and raised its adjusted EPS outlook for fiscal 2025.

Analyst Outlook: Analysts maintain a "Strong Buy" consensus on Cencora, which is currently trading below the mean price target of $282.07, indicating positive investor sentiment compared to its rival McKesson Corporation, which has shown slightly lower year-to-date performance.

CENCORA INC Analysis: CENCORA INC (COR) is rated 68% using the Multi-Factor Investor model, which focuses on low volatility stocks with strong momentum and high net payout yields, indicating moderate interest based on its fundamentals and valuation.

Pim van Vliet's Strategy: Pim van Vliet, head of Conservative Equities at Robeco Asset Management, emphasizes that low volatility stocks can outperform high volatility ones with less risk, a concept he explores in his book "High Returns From Low Risk."

Company Overview: McKesson Corporation, valued at $80.4 billion, is a major healthcare services and IT company with four segments, but its stock has declined 9.6% from its 52-week high despite outperforming the Dow Jones in recent months.

Financial Performance: Following a weaker-than-expected Q3 earnings report, McKesson's shares fell 1.2%, raising concerns about revenue declines in its Medical-Surgical Solutions segment and negative free cash flow, although it maintains a "Strong Buy" rating from analysts.

GARP Investment Strategy: The article discusses the GARP (Growth at a Reasonable Price) investment strategy, which focuses on undervalued stocks with solid growth prospects, highlighting three promising stocks: Sprouts Farmers Market, Cencora, Inc., and American Express.

Stock Performance and Projections: Each of the featured companies has shown significant growth in the past year and positive earnings projections for 2025, indicating their potential as strong investment opportunities within the GARP framework.

Florida's Data Request: The Florida Office of Insurance Regulation is requesting detailed pharmacy claims data from pharmacy benefit managers (PBMs), including personal information such as names, birth dates, and medication details.

Privacy Concerns: A spokesperson for the Florida OIR stated that any privacy issues should be directed to health-care insurance companies, which have previously experienced significant data breaches.

Put Contract Analysis: The $230.00 put contract for COR stock offers a potential cost basis of $229.45, representing a 6% discount from the current price, with a 79% chance of expiring worthless and providing a 1.56% annualized return if it does.

Call Contract Overview: The $250.00 call contract allows investors to sell shares at a premium, potentially yielding a 4.00% return if exercised, with a 57% chance of expiring worthless, which would result in an 11.73% annualized return from the premium collected.

GARP Investment Strategy: The article discusses the Growth at a Reasonable Price (GARP) investment strategy, which focuses on identifying stocks that are undervalued yet have strong growth potential, highlighting American Express, Cencora, and Tempur Sealy International as promising GARP stocks.

Stock Performance and Metrics: It emphasizes key metrics for GARP investors, such as earnings growth, return on equity, and price-to-earnings ratios, while providing recent performance data and future earnings estimates for the mentioned companies.

Company Overview and Performance: Cencora, Inc., a pharmaceutical services company with a market cap of $47.7 billion, has seen its shares underperform the broader market over the past year but has shown improvement in 2025, outperforming both the S&P 500 and the VanEck Pharmaceutical ETF.

Earnings Report and Analyst Ratings: Following a strong Q4 earnings report that exceeded revenue expectations, Cencora raised its full-year EPS guidance, resulting in an upgrade to a "Strong Buy" consensus rating from analysts, with a price target increase reflecting potential upside for investors.

Upcoming Ex-Dividend Dates: Cencora Inc, Bio-Techne Corp, and Eli Lilly will trade ex-dividend on 2/14/25, with respective dividends of $0.55, $0.08, and $1.50 scheduled for payment on 3/3/25, 2/28/25, and 3/10/25.

Market Impact and Dividend Yields: Following the ex-dividend date, shares are expected to open lower by approximately 0.22% for Cencora Inc, 0.12% for Bio-Techne Corp, and 0.17% for Eli Lilly; estimated annualized yields are 0.89%, 0.47%, and 0.69% respectively.

Warren Buffett's Investment Strategy: The investment strategy that contributed to Warren Buffett's success as a multibillionaire is no longer effective.

Changing Market Conditions: The decline in effectiveness of this strategy is not due to the usual reasons one might expect.

Insider Trading Activity: Walgreens Boots Alliance, Inc. sold over 1 million shares of $COR, reducing their ownership by approximately 5.4%, while insiders have conducted 9 sales and no purchases in the past 6 months.

Institutional Investor Movements: In the latest quarter, 576 institutional investors increased their positions in $COR stock, while 497 decreased theirs, indicating mixed sentiment among institutional holders.

Earnings Report Announcement: Humana is set to release its fourth-quarter 2024 earnings report on February 11, with analysts expecting a revenue growth of 12% year-over-year to $28.83 billion and an adjusted loss of $2.12 per share.

Stock Performance Overview: Humana's stock has dropped 2.37% recently but is up 5.58% year-to-date; however, it has fallen 27.73% over the past year, raising investor interest in its growth trajectory compared to peers like Centene and Cencora.

Target Corp Options Activity: Target Corp (TGT) has seen significant options trading today with 34,877 contracts, equating to about 3.5 million underlying shares, particularly notable for the $140 strike call option expiring February 14, 2025.

Cencora Inc Options Activity: Cencora Inc (COR) recorded a trading volume of 9,474 contracts, representing approximately 947,400 underlying shares, with high activity noted for the $220 strike put option expiring January 16, 2026.

Walgreens Boots Alliance Settlement: Walgreens Boots Alliance has reached an early settlement for prepaid variable share forward transactions, transferring approximately 6.1 million shares of Cencora and receiving about $300 million from the settlement and concurrent sale of shares, while reducing its stake in Cencora from 10% to 6%.

Financial Strategy Adjustments: The proceeds from these transactions will primarily be used for debt reduction and corporate purposes, as Walgreens also announced a suspension of its quarterly dividend to align with its long-term recovery strategy.